Download Files:
Z-Asp-CH2-DCB
SKU
HY-113953-1 mg
Category Reference compound
Tags Apoptosis, Apoptosis;Caspase, Inflammation/Immunology
$50 – $130
Products Details
Product Description
– Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development[1][2][3].
Web ID
– HY-113953
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C20H17Cl2NO7
References
– [1]Krakauer T, et al. Caspase inhibitors attenuate superantigen-induced inflammatory cytokines, chemokines, and T-cell proliferation. Clin Diagn Lab Immunol. 2004 May;11(3):621-4.|[2]Kasahara Y, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000 Dec;106(11):1311-9.|[3]Twumasi P, et al. Caspase inhibitors affect the kinetics and dimensions of tracheary elements in xylogenic Zinnia (Zinnia elegans) cell cultures. BMC Plant Biol. 2010 Aug 6;10:162.
CAS Number
– 153088-73-4
Molecular Weight
– 454.26
Compound Purity
– 99.28
SMILES
– O=C(OCC([C@@H](NC(OCC1=CC=CC=C1)=O)CC(O)=O)=O)C2=C(Cl)C=CC=C2Cl
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Apoptosis;Caspase
Pathway
– Apoptosis
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.